Five reasons to buy AstraZeneca
The general consensus is that the decline in AstraZeneca’s share price now represents a good buying opportunity
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1094 stories · page 10 of 11
AstraZeneca's MYSTIC trial has little appeal for JP Morgan
The broker’s target price drops to £46 from £49 and the rating remains hold.
AztraZeneca a bargain, says this stock picker
The unwinding of bid speculation has meant AZ has lost around 15% of its value in the last six months.
FTSE 100 closed firm but volumes thin
FTSE 100 shares managed to recover enough to close Friday firmer but volumes were held back by the half-day trading in New York following Thanksgiving holiday on Thursday
AstraZeneca restarts cancer drug trials after US all clear
The two trials, KESTREL and EAGLE, are for head and neck cancer sufferers
Is too great a risk of MYSTIC failure factored into AstraZeneca's price?
Berenberg ascribes a 75% chance of success for the MYSTIC first-line lung cancer study, whereas the market seems more sceptical
It's all about the pipelines for drugs giants Astra and Shire
Exane has a target price of 5,100p for Astra, versus a current price of 4,406p. DB’s valuation of 6,200p per share for Shire is more than a tenner above the current price of around 5,020p.
AstraZeneca trial shows benefit of child asthma treatment
The improvement demonstrated the drug's appropriateness as a step-up therapy in young children
Immuno-therapy trials key for AstraZeneca says broker
Astra’s revenues fell 4% in the three months to September to US$5.7bn
AstraZeneca a highlight for a busy City schedule for Thursday
AstraZeneca, Vedanta, Halfords, and SuperGroup were among those in Thursday's diary.
Risers and fallers: Fresnillo glistens, while Tate's in a state
Some of the main news-driven share price changes at 3.30pm.
Drugs stocks boosted by Clinton defeat
Markets have reacted badly to Trump's electoral victory, but some sectors have benefited
Archive
Brokers: UK pharma giants in good shape if Clinton wins says Citigroup
“From a legislative angle, we continue to prefer names with either limited part D exposure [US Medicare] or heavier contribution of non-pharma assets."
Week Ahead: US election takes centre stage
Aside from the election, several UK retailers have results due next week
Investments and investor services
FTSE 100 drops on miners and drugs
FTSE 100 shares fell on Monday led by pharma Hikma
Proactive news summary – Mirada, Tissue Regenix, Synairgen and Vast Resources
A selection of the day's significant news stories from the junior AIM market
Archive
Salesforce.com gets battered but it has a fan in Exane
Exane is less concerned about any potential bid by Salesforce.com for Twitter than it is about the exciting deal it has just done
Investments and investor services
FTSE 100 nears May 2015 highs after data and sterling fall
FTSE 100 shares had a good start to the fourth quarter, helped by good manufacturing data and hopes that the pound's sharp fall on Monday will help exporters
RBS has a shocker post-Brexit
It was better news for the miners which have rallied since June’s EU referendum
AstraZeneca up after diabetes combo passes phase III
The trial met the met the primary endpoint of a better performance that the single medicines alone said the pharma
Ocado gets another pasting over margin warning
Exane BNP Paribas downgrades online grocer after it warned of margin pressure from rivals
Broker talks up AstraZeneca's lung cancer drug prospects
Jefferies upgraded the health giant to a 'buy' recommendation
Investments and investor services
London shares close lower as Fed Lockhart comments boost US rate hike risk
London shares ended lower on Monday after comments from Fed official Dennis Lockhart added to the chorus of central bankers calling US rates higher next week
Redx Pharma welcomes former AstraZeneca executive
Karl Hård, formerly at pharma titan AstraZeneca PLC has joined executive management as head of investor relations and corporate communications
AstraZeneca’s new asthma drug: “Late to the game, but potentially best in class”
This week AstraZeneca announced a next-generation asthma drug that would see it locking horns with fellow pharma giants over treatments already out there.
AstraZeneca asthma treatment does well in final trial
The new drug reduced wheeze, cough, chest tightness and shortness of breath
UK shares surge, rub out previous day’s losses, as miners stage a comeback
London shares closed sharply higher on Friday and more than erased the previous session’s losses as two unlikely bedfellows – tobacco and pharma stocks – led the gains alongside a rebound by miners which had a difficult week
FTSE 100 sitting pretty ahead of US jobs report
An unlikely combination of tobacco and drugs stocks are driving the top-share index's advance
UK stocks gains after Fed’s Yellen comments, miners dominate after zinc price gains
London stocks closed higher on Friday, feeding off the initial optimism of Wall Street investors over comments from the US central bank’s chief Janet Yellen, while 15-month highs for zinc prices made miners dominate the skyline
FTSE 100 inches higher as investors wait on Yellen
FTSE 100 added 8 to 6,825 and the FTSE AIM 0.4% to 792.5
Archive
Risers & fallers: Avanti Communications, San Leon Energy, Osirium Technologies, Bellzone Mining, Alexander Mining
Here we put the spotlight on Friday's market movers
UK shares close lower, wary of Fed speech, pharma dragged down by Clinton remarks
London shares closed lower on Thursday, nestled in negative territory throughout the session, as investors turned wary ahead of Fed chair Janet Yellen’s speech at Jackson Hole on Friday and pharma stocks were singed by Hillary Clinton’s pro
Mylan boss take the fight to Hillary
Mylan reacted by announcing plans to boost access to the product by expanding already-existing programs for patients who face what’s called out-of-pocket expenses.
Shire leads the fallers as £3.7bn is wiped from drugs sector after Clinton blast
Hilary Clinton took aim at one US drugs company - yet the shock waves were felt here in London.
AstraZeneca to sell antibiotics business to Pfizer
The deal is for its late-stage small molecule antibiotics business and involves three already-approved antibiotics - Merrem, Zinforo and Zavicefta - and two drugs in clinical trials (ATM-AVI and CXL).
Medivation faces buyers’ scrum - report
A scrum to acquire US cancer drug company Medivation was emerging on Wednesday after reports that Merck, Pfizer and Gilead Sciences were among at least five pharmaceutical companies expressing an interest
London stocks fall as oil prices hit six-week highs
London blue-chip stocks closed at their session nadir on Tuesday and their lowest since Thursday as a miners’ rally failed to buttress the main line ticker as oil prices hit six-week highs in Europe
FTSE 100 marks time despite buoyant mining sector
Blue-chips are becalmed after opening lower, though mining stocks continue to provide some cheer
FTSE 100 drifts lower despite demand for miners
The top seven Footsie performers are all miners, with Antofagasta topping the list after its half-year update
AstraZeneca combination fails final lung cancer trial, Array hit
Astra’s announcement was the second disappointing outcome for NSCLC sufferers in the space of a week.
Cantor sees much more upside for Sound Energy after Morocco breakthrough
Sound Energy shares have already climbed more than 250% since early July, but according Cantor's upgraded target there remains plenty of upside.
UK shares end softer as demand surges for gilts on rate cut talk
London's blue-chip stocks ended lower on Thursday after a session spent mostly suspended beneath the previous closing level as investors sought safer haven in UK government bonds, or gilts
Banking and oil woe drags FTSE 100 Index lower
The FTSE 100 Index was 6.56 points adrift at 6,743.87 in lunchtime trading
Generics hound AstraZeneca despite Brilinta star turn
New products saw an 8% sales rise to US$3.7bn with new heart disease drug Brilinta especially strong
Footsie treads water amid negative news from Lloyds
The FTSE 100 Index was 3.2 points adrift at 6,747.24 in early trading
PREVIEW: Investors look for signs of synergies from Shell's acquisition of BG
To misquote Prince, it’s just another frantic Thursday with around one-sixth of the FTSE 100 companies set to update the market.
Bid war beckons after Galenica snaps up Relypsa, brokers say
Brokers forecast rival interest after Galenica snaps up Relypsa for US$1.53bn
Successful lung cancer drug trial boosts AstraZeneca
Drug giant said a phase III trial of Tagrisso had met its primary endpoint
FTSE 100 Index closes lower on mild profit taking
London's blue chips shed a couple of points at the close after gains earlier
Investments and investor services
FTSE 100 Index treads water as market awaits Carney comments
The Footsie fell 0.18 points to 6682.68 in early trading
London stocks close at 11-month highs after S&P500 hits new record
London shares closed on Monday at their highest level in exactly eleven months, feeding off Wall Street’s record levels
Footsie gains as traders eye possible interest rate cut
The FTSE 100 Index climbed 55.17 points while M&A talk involving AstraZeneca re-emerged
FTSE 100 closes above Brexit crisis levels
London’s FTSE 100 index on Wednesday closed above “Brexit” crisis levels for the first time since the morning of the In-Out European Union referendum polling last Thursday
Archive
Brokers pick their winners post-Brexit
Broadcaster ITV was downgraded, as was airline group IAG
Investments and investor services
BREXIT LIVE: City reaction as Britons choose leave
That's it from us for a very volatile Friday, more Brexit reaction to follow on Monday.
AstraZeneca to take impairment after US recommends against flu vaccine
Astra said its findings differed from those of the US CDC
AstraZeneca does US$770mln anaesthetic deal
British drug group said Aspen will acquire commercialisation rights to its anaesthetic medicines outside the US
Ireland-focused oil firms boosted as FTSE 100 Index rises
The FTSE 100 Index closed 24.02 points up at 6209.63
AstraZeneca bags US rights for gout-related drug
British drug group acquires exclusive US rights to Zurampic
Archive
FDA's ZS-9 ruling just a "bump in the road" for AstraZeneca
News from drugs giant Astra this morning was like the proverbial curate’s egg: good in parts.
AstraZeneca drug fails gastric cancer trial
Drug company says Lynparza fell short of hopes in phase three trial
Archive
No jumps on the way for William Hill, says Canaccord
Bookmaker William Hill has its target lowered by City broker Canaccord.....
FTSE 100 retreats late as miners suffer, small caps steady
Shares in London fall back late on despite solid start
Archive
Brokers: RBS downgrade as UBS frets over payout potential
Also, Tullow Oil, Astra Zeneca, Next, Armadale Capital, Eland Oil...
AstraZeneca to cut costs but stays silent on M&A talk
UK drug giant set to focus on cancer drugs but declines to comment on Medivation takeover speculation
Broker sees possible higher bid for Medivation
French drug group offers US$9.3bn for prostate cancer specialist
PREVIEW: Can AstraZeneca follow Glaxo with better-than-expected quarterlies?
AstraZeneca releases first quarter results on Friday, the schedule also includes Shire, BA owner International Consolidated Airlines, and Royal Bank of Scotland Group.
UK shares finish as they started as traders eye Fed meet
UK shares ended the day in similar fashion as they begun, with big caps outshining smaller stocks.
Week Ahead: Investors look out for Apple, Twitter, Facebook and BP results
After Silicon Valley giants Alphabet and Microsoft disappointed this week, next Tuesday brings Apple Inc’s second-quarter earnings.
London shares recover after oil-stained session
The FTSE 100 Index closed 9.77 points higher at 6,353
AstraZeneca tipped to bid for US cancer specialist
AstraZeneca has reportedly held talks with San Francisco-based Medivation
Small caps recover from oil woe as drug M&A talk swirls
Small caps pare losses but Footsie drops nearly 20 points
Stocks dip after oil talks fail, but drug M&A chat injects interest
Indices drop after Iran's absence at talks scuppers hopes of price freeze
Archive
Unilever catches Credit Suisse’s eye
Credit Suisse is bullish on consumer goods giant Unilever PLC ahead of first quarter results on April 14 and has ramped up the target price.
AstraZeneca PLC's US$100mln boost as Eli Lilly collaboration moves to next stage
Lilly has made what’s known as a milestone payment following progress in developing a treatment called AZD3293 for early stage Alzheimer's disease.
Investments and investor services
Stocks advance, led by Botswana Diamonds PLC and Cyan Holdings PLC
Throughout the day Botswana Diamonds and Cyan Holdings competed to be the biggest riser on the day.
Trending: Pfizer tie up with Allergan catches a cold
Not for the first time has the ambitious and acquisitive pharmaceutical behemoth Pfizer has been upset at the merger altar, but with its Allergan deal under threat, the company may well step back and assess shareholder value
Archive
Drug companies inject interest into lacklustre London market
PureTech Health told investors it had expanded its focus on microbiome-based interventions
AstraZeneca's heart drug Brilinta fails in trial
Drug group said blood-thinning treatment missed targets for reducing repeat stroke and heart attacks
Synairgen makes progress with lung drug
Lung drug developer says tests showed success in treating idiopathic pulmonary fibrosis
Archive
AstraZeneca PLC lacks catalysts for 2016 - Jefferies
Broker Jefferies has cut its rating on drugs giant AstraZeneca PLC to 'hold' from 'buy' saying there's a lack of catalysts in 2016 to re-rate shares.
RedX tipped for success as Cantor assesses pharmas
Cantor now rates RedX as a ‘buy’, and with a 105p target the broker sees some 150% upside to the current price of 41.5p.
Archive
Jefferies downgrades targets on Glaxo and Astra
US heavyweight Jefferies looks at global pharma today and downgraded Glaxo and AstraZeneca...
Archive
FTSE 100 makes good ground despite Brexit talk
Footsie was buoyed by a good start to the week;s trading on Wall Street
FTSE100 posts solid gains as Brexit talks slays sterling
FTSE 100 climbed 76 points to 6,026 despite a tough day for the pound
FTSE 100 in ton-up mode
Miners lead the march of the blue-chips while among the small caps it is more a case of the salsa
AstraZeneca gets US boost for bladder cancer drug
Drug group gets "breakthrough therapy" designation for durvalumab in the US
Investments and investor services
London shares take cue from strong Wall Street performance
The FTSE 100 Index rose in early trading after the Dow Jones Industrial Average closed 223 points ahead
Trending - Today's unfounded big pharma merger rumor is ...
A whisper to a scream ... rumors of another big pharma merger are gaining volume
Archive
FTSE 100 lifted by resource stocks
Resource stocks were back in favour big-time today, helped by a softer US sollar
Market bounces amid oil supply cut talk
The FTSE 100 Index was 56.86 points up at 5894 at lunchtime
Investments and investor services
Footsie climbs back above 5,900 as oil prices rebound
The FTSE 100 Index gained 64.07 points to 5901 in early trading
Risers & Fallers: First Quantum, Galasys, IPSA, Motive Television, Plethora Solutions, Tribal Group
AstraZeneca is on a downer after it warns revenue and profits will be lower this year than last but Shell keeps going well